Fig. 2From: Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistanceTornado diagram for one-way sensitivity analyses. PFS, progression-free survival; PD, progressive disease; AEs, adverse events; ICER, incremental cost-effectiveness ratio; ASTI, androgen-signaling-targeted inhibitorBack to article page